Literature DB >> 8452534

Demonstration of adenosine deaminase activity in human fibroblast lysosomes.

E R Lindley1, R L Pisoni.   

Abstract

Human fibroblast lysosomes, purified on Percoll density gradients, contain an adenosine deaminase (ADA) activity that accounts for approximately 10% of the total ADA activity in GM0010A human fibroblasts. In assays of lysosomal ADA, the conversion of [3H]adenosine into [3H]inosine was proportional to incubation time and the amount of lysosomal material added to reaction mixtures. Maximal activity was observed between pH 7 and 8, and lysosomal ADA displayed a Km of 37 microM for adenosine at 25 degrees C and pH 5.5. Lysosomal ADA was completely inhibited by 2.5 mM Cu2+ or Hg2+ salts, but not by other bivalent cations (Ba2+, Cd2+, Ca2+, Fe2+, Mg2+, Mn2+ and Zn2+). Coformycin (2.5 mM), deoxycoformycin (0.02 mM), 2'-deoxyadenosine (2.5 mM), 6-methylaminopurine riboside (2.5 mM), 2'-3'-isopropylidene-adenosine (2.5 mM) and erythro-9-(2-hydroxy-3-nonyl)adenine (0.2 mM) inhibited lysosomal ADA by > 97%. In contrast, 2.5 mM S-adenosyl-L-homocysteine and cytosine were poor inhibitors. Nearly all lysosomal ADA activity is eluted as a high-molecular-mass protein (> 200 kDa) just after the void volume on a Sephacryl S-200 column, and is very heat-stable, retaining 70% of its activity after incubation at 65 degrees C for 80 min. We speculate that compartmentalization of ADA within lysosomes would allow deamination of adenosine to occur without competition by adenosine kinase, which could assist in maintaining cellular energy requirements under conditions of nutritional deprivation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452534      PMCID: PMC1132295          DOI: 10.1042/bj2900457

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  46 in total

1.  Human adenosine deaminase. Purification and subunit structure.

Authors:  P E Daddona; W N Kelley
Journal:  J Biol Chem       Date:  1977-01-10       Impact factor: 5.157

2.  Human adenosine deaminase. Distribution and properties.

Authors:  M B Van der Weyden; W N Kelley
Journal:  J Biol Chem       Date:  1976-09-25       Impact factor: 5.157

Review 3.  Mechanism of action and structure of acid deoxyribonuclease.

Authors:  G Bernardi
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  1968

4.  Kinetics and the mechanism of action of adenosine aminohydrolase.

Authors:  B A Orsi; N McFerran; A Hill; A Bingham
Journal:  Biochemistry       Date:  1972-08-29       Impact factor: 3.162

5.  Purification and properties of an acid nucleotidase from rat liver lysosomes.

Authors:  C Arsenis; O Touster
Journal:  J Biol Chem       Date:  1968-11-10       Impact factor: 5.157

6.  Degradation of nucleic acids by lysosomal extracts of rat liver and Ehrlich ascites tumor cells.

Authors:  C Arsenis; J S Gordon; O Touster
Journal:  J Biol Chem       Date:  1970-01-10       Impact factor: 5.157

7.  Multiple forms of human adenosine deaminase. I. Purification and characterization of two molecular species.

Authors:  H Akedo; H Nishihara; K Shinkai; K Komatsu; S Ishikawa
Journal:  Biochim Biophys Acta       Date:  1972-07-13

8.  Adenosine deaminase from calf spleen. II. Chemical and enzymological properties.

Authors:  N Pfrogner
Journal:  Arch Biochem Biophys       Date:  1967-03       Impact factor: 4.013

9.  Association of adenosine deaminase with erythrocyte and platelet plasma membrane: an immunological study using light and electron microscopy.

Authors:  R Franco; J M Aran; D Colomer; E Matutes; J L Vives-Corrons
Journal:  J Histochem Cytochem       Date:  1990-05       Impact factor: 2.479

10.  Characterization of residual enzyme activity in fibroblasts from patients with adenosine deaminase deficiency and combined immunodeficiency: evidence for a mutant enzyme.

Authors:  R Hirschhorn; N Beratis; F S Rosen
Journal:  Proc Natl Acad Sci U S A       Date:  1976-01       Impact factor: 11.205

View more
  9 in total

1.  Inhibition of Transient Receptor Potential Channel Mucolipin-1 (TRPML1) by Lysosomal Adenosine Involved in Severe Combined Immunodeficiency Diseases.

Authors:  Xi Zoë Zhong; Yuanjie Zou; Xue Sun; Gaofeng Dong; Qi Cao; Aditya Pandey; Jan K Rainey; Xiaojuan Zhu; Xian-Ping Dong
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

2.  NUFIP1 is a ribosome receptor for starvation-induced ribophagy.

Authors:  Gregory A Wyant; Monther Abu-Remaileh; Evgeni M Frenkel; Nouf N Laqtom; Vimisha Dharamdasani; Caroline A Lewis; Sze Ham Chan; Ivonne Heinze; Alessandro Ori; David M Sabatini
Journal:  Science       Date:  2018-04-26       Impact factor: 47.728

3.  Biochemical characterization of adenosine deaminase (CD26; EC 3.5.4.4) activity in human lymphocyte-rich peripheral blood mononuclear cells.

Authors:  L R Costa; A K Y de Souza; J N Scholl; F Figueiró; A M O Battastini; J A Dos Santos Jaques; F F Zanoelo
Journal:  Braz J Med Biol Res       Date:  2021-05-24       Impact factor: 2.590

4.  Altered microRNA expression and pre-mRNA splicing events reveal new mechanisms associated with early stage Mycobacterium avium subspecies paratuberculosis infection.

Authors:  Guanxiang Liang; Nilusha Malmuthuge; Yongjuan Guan; Yuwei Ren; Philip J Griebel; Le Luo Guan
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

5.  Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis.

Authors:  Scott P Allen; Benjamin Hall; Lydia M Castelli; Laura Francis; Ryan Woof; Alexandros P Siskos; Eirini Kouloura; Elizabeth Gray; Alexander G Thompson; Kevin Talbot; Adrian Higginbottom; Monika Myszczynska; Chloe F Allen; Matthew J Stopford; Jordan Hemingway; Claudia S Bauer; Christopher P Webster; Kurt J De Vos; Martin R Turner; Hector C Keun; Guillaume M Hautbergue; Laura Ferraiuolo; Pamela J Shaw
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

6.  Ral GEF with the PH Domain and SH3 Binding Motif 1 Regulated by Splicing Factor Junction Plakoglobin and Pyrimidine Metabolism Are Prognostic in Uterine Carcinosarcoma.

Authors:  Hongjun Guo; Siqiao Wang; Aiqing Xie; Wenhuizi Sun; Chenlu Wei; Shuyuan Xian; Huabin Yin; Mingxiao Li; Hanlin Sun; Hong Li; Tong Meng; Jie Zhang; Zongqiang Huang
Journal:  Dis Markers       Date:  2021-10-28       Impact factor: 3.434

Review 7.  Targeting purine metabolism in ovarian cancer.

Authors:  Jingchun Liu; Shasha Hong; Jiang Yang; Xiaoyi Zhang; Ying Wang; Haoyu Wang; Jiaxin Peng; Li Hong
Journal:  J Ovarian Res       Date:  2022-08-13       Impact factor: 5.506

8.  FAMIN Is a Multifunctional Purine Enzyme Enabling the Purine Nucleotide Cycle.

Authors:  M Zaeem Cader; Rodrigo Pereira de Almeida Rodrigues; James A West; Gavin W Sewell; Muhammad N Md-Ibrahim; Stephanie Reikine; Giuseppe Sirago; Lukas W Unger; Ana Belén Iglesias-Romero; Katharina Ramshorn; Lea-Maxie Haag; Svetlana Saveljeva; Jana-Fabienne Ebel; Philip Rosenstiel; Nicole C Kaneider; James C Lee; Trevor D Lawley; Allan Bradley; Gordon Dougan; Yorgo Modis; Julian L Griffin; Arthur Kaser
Journal:  Cell       Date:  2020-01-23       Impact factor: 41.582

9.  The lysosome: A potential juncture between SARS-CoV-2 infectivity and Niemann-Pick disease type C, with therapeutic implications.

Authors:  Rami A Ballout; Dmitri Sviridov; Michael I Bukrinsky; Alan T Remaley
Journal:  FASEB J       Date:  2020-05-05       Impact factor: 5.834

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.